NEW YORK, June 12, 2019 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Medidata Solutions (NASDAQ: MDSO) on behalf of Medidata shareholders concerning the proposed merger with Dassault Systèmes (Other OTC: DASTY).
Click here to participate in the action.
Pursuant to the proposed transaction, announced on June 12, 2019 and valued at $5.8 billion, Medidata shareholders will receive $92.50 for each share of Medidata common stock owned. The investigation focuses on whether Medidata and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own Medidata shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], or telephone at (212) 308-1869, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation of Medidata please go to https://bespc.com/mdso/. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
Latest posts by GlobeNewswire (see all)
- REV DEADLINE: Rosen, a Highly Ranked Law Firm, Reminds Revlon, Inc. Investors of Important July 15th Deadline in Securities Class Action – REV - June 15, 2019
- ROADSTER-2 Demonstrates Compelling Patient Outcomes with Strong Safety Profile - June 15, 2019
- Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting - June 15, 2019